Rheumatology Advance Access published online on May 16, 2006
Rheumatology, doi:10.1093/rheumatology/kel142
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Centre for Inflammatory Diseases, Monash Institute for Medical Research, Monash Medical Centre, Clayton, Melbourne, Australia
* To whom correspondence should be addressed. Glucocorticoids (GCs) are widely used in the treatment of inflammatory diseases including rheumatoid arthritis (RA). Treatment with GC is associated with significant dose-dependent side-effects. The pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) has emerged in recent years as a candidate factor which could regulate GC sensitivity. MIF is induced by GC, and is able to override anti-inflammatory actions of GCs. In this review, we summarize the pro-inflammatory actions of MIF with respect to RA, describe the interactions between MIF and GC and examine new evidence, which identifies MIF as a specific target for steroid sparing.
Received November 2, 2005
Accepted February 27, 2006
Review
Macrophage migration inhibitory factor and glucocorticoid sensitivity
D. Aeberli 1,
M. Leech 1,
and
E. F. Morand 1 *
E. F. Morand, E-mail: eric.morand{at}med.monash.edu.au
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?